Amundi’s Kyntra Bio KYNB Stock Holding History

Amundi’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-208	Closed	-$138K	–	1586
2021 Q2	$138K	Buy	+208	New	+$120K	﹤0.01%	1442

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi's KYNB Position: Q3 2021 in Review

Amundi sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 208 shares — an estimated $138K sold.

Amundi first reported a position in KYNB in Q2 2021 and held it in 1 quarter. The position peaked at $138K in Q2 2021. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

Amundi reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
Amundi sold 208 Kyntra Bio shares in Q3 2021, an estimated $138K.
Amundi first reported a position in Kyntra Bio in Q2 2021 and held it in 1 quarter.
Amundi's Kyntra Bio position peaked at $138K in Q2 2021.
164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Amundi's 13F filing for Q3 2021, filed 15 Nov 2021.